KLK4 Is A Master Regulator Of Tumour Microenvironment Remodelling In Prostate Cancer And Bone Metastasis
Funder
National Health and Medical Research Council
Funding Amount
$596,305.00
Summary
The current biomarker for prostate cancer, PSA, belongs to a large family of related proteins called KLK enzymes. We have evidence that one of these enzymes, KLK4, regulates many different pathways involved in tumour spreading especially to bones. This project will determine the specific components involved with a view to finding better biomarkers of tumour spread and bone metastasis and designing better treatments for these aspects of the disease.
Development and validation of virtual epithelial cancer models using an integrated modelling and experimental three-dimensional approach. The mathematical and experimental modelling of the human prostate and ovary applying quantitative bioengineering concepts will lead to virtual cancer models. This project aims to validate these multi-scale models to delineate biological and pathological avenues in healthy and disease tissue and improve prevention and treatment of prostate and ovarian cancer.